Disclosed are methods of dopamine transporter (DaT) visualization in the brain of a subject (e.g., a subject suspected of suffering from Parkinson's disease, dementia with Lewy bodies, or Alzheimer's disease). The methods typically include the step of intravenous administration to the subject of a first dose of [123I]altropane and the step of acquiring SPECT counts from the subject's brain (e.g., obtaining a first number of SPECT counts of the subject's brain). If the first number of SPECT counts is less than the number indicating that a final SPECT image is obtainable within one SPECT session, then the subject is uptitrated using one or more intravenous administrations of [123I]altropane in the increments of, e.g., 0.5-3 mCi of [123I]altropane, until the number of acquired SPECT counts indicates that a final SPECT image may be obtained.
Disclosed is an individualized dosing method of imaging the DAT receptors in a region of interest in the body of a subject using multiples of suboptimal packaging units of radiolabeled tracer, and kits for doing the same.
This disclosure relates to methods of determining if a subject not manifesting any clinical symptoms of a dopaminergic disorder is afflicted with the dopaminergic disorder using radiolabeled DatT020 or a derivative thereof.
Disclosed is a method of increasing the rate of delivery of an active compound or agent to the brain across the blood brain barrier of a subject. In one aspect, the disclosure provides an accelerated method of providing an active compound to a targeted region of the brain of a subject, served by the cerebral medial artery, the method comprising: administering a sub-anesthetic dose of xenon as an inhalant to the subject; and administering an efficacious amount of the active compound to the bloodstream of the subject, the active compound reaching the targeted region of the brain in less time relative to a time it takes to reach the targeted region without xenon administration.
A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
Provided are methods of evaluating an ability of a therapeutic composition to modulate a dopaminergic activity in an organ of a mammalian subject having a dopaminergic disorder. Also provided are methods of assessing and monitoring the progression of a dopaminergic disorder in tan organ of a mammalian subject, and of optimizing the treatment of such a disorder.
Disclosed are methods of predicting the risk of developing a neurological disorder in a mammalian subject and methods of use of this profile for providing neuroanalytical services for an end user. Also disclosed is a system comprising a processor and a memory having a neurodiagnostic algorithm and plurality of data sets, the processor being capable of reading the data sets, executing the neurodiagnostic algorithm, and deriving a risk profile therefrom.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
C07D 451/02 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamineCyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropaneCyclic acetals thereof
G21H 5/02 - Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for as tracers
C07D 451/02 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamineCyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropaneCyclic acetals thereof
G21H 5/02 - Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for as tracers
Presented is a method for assessing dopamine transporterlevels in a selected area of a subject's central nervous system by SPECTimaging comprising administering an injection of a labeled dopaminetransporter ligand at approximately the time the subject is positionedfor SPECT imaging and initiating a SPECT acquisition for a duration ofabout 30 minutes commencing at about 15 minutes after administrationof labeled dopamine transporter ligand; and assessing, based on saidSPECT acquisition, the amount of labeled dopamine transporter ligandthat is bound to dopamine transporter.
Presented is a method for assessing dopamine transporter levels in a selected area of a subject's central nervous system by SPECT imaging comprising administering an injection of a labeled dopamine transporter ligand at approximately the time the subject is positioned for SPECT imaging and initiating a SPECT acquisition for a duration of about 30 minutes commencing at about 15 minutes after administration of labeled dopamine transporter ligand; and assessing, based on said SPECT acquisition, the amount of labeled dopamine transporter ligand that is bound to dopamine transporter.
patents
